Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

被引:0
|
作者
Makiko Ono
Hitoshi Tsuda
Chikako Shimizu
Sohei Yamamoto
Tatsuhiro Shibata
Harukaze Yamamoto
Taizo Hirata
Kan Yonemori
Masashi Ando
Kenji Tamura
Noriyuki Katsumata
Takayuki Kinoshita
Yuichi Takiguchi
Hideki Tanzawa
Yasuhiro Fujiwara
机构
[1] National Cancer Center Hospital,Breast and Medical Oncology Division
[2] National Cancer Center Hospital,Clinical Laboratory Division, Department of Pathology
[3] National Defense Medical College,Department of Basic Pathology
[4] Center for Medical Genomics,Cancer Genomics Project, Pathology Division
[5] National Cancer,Breast Surgery Division
[6] Center Research Institute,Department of Respirology
[7] National Cancer Center Hospital,Department of Clinical Molecular Biology
[8] Graduate School of Medicine,undefined
[9] Chiba University,undefined
[10] Graduate School of Medicine,undefined
[11] Chiba University,undefined
来源
关键词
Triple-negative breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Tumor-infiltrating lymphocytes; Tumor cell apoptosis;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of the present study was to identify histological surrogate predictive markers of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC). Among 474 patients who received NAC and subsequent surgical therapy for stage II–III invasive breast carcinoma between 1999 and 2007, 102 (22%) had TNBC, and 92 core needle biopsy (CNB) specimens obtained before NAC were available. As controls, CNB specimens from 42 tumors of the hormone receptor-negative and HER2-positive (HR−/HER2+) subtype and 46 tumors of the hormone receptor-positive and HER2-negative (HR+/HER2−) subtype were also included. Histopathological examination including tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis, and immunohistochemical studies for basal markers were performed, and the correlation of these data with pathological therapeutic effect was analyzed. The rates of pCR at the primary site were higher for TNBC (32%) and the HR−/HER2+ subtype (21%) than for the HR+/HER2− subtype (7%) (P = 0.006). Expression of basal markers and p53, histological grade 3, high TIL scores, and apoptosis were more frequent in TNBC and the HR−/HER2+ subtype than in the HR+/HER2− subtype (P = 0.002 for TIL and P < 0.001 for others). In TNBC, the pCR rates of tumors showing a high TIL score and of those showing a high apoptosis score were 37 and 47%, respectively, and significantly higher or tended to be higher than those of the tumors showing a low TIL score and of the tumors showing a low apoptosis score (16 and 27%, respectively, P = 0.05 and 0.10). In a total of 180 breast cancers, the pCR rates of the tumors showing a high TIL score (34%) and of those showing a high apoptosis score (35%) were significantly higher than those of the tumors showing a low TIL score (10%) and those of the tumors showing a low apoptosis score (19%) (P = 0.0001 and 0.04, respectively). Histological grade and basal marker expression were not correlated with pCR. Although the whole analysis was exploratory, the degree of TIL correlated with immune response appear to play a substantial role in the response to NAC in TNBC.
引用
收藏
页码:793 / 805
页数:12
相关论文
共 50 条
  • [21] Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
    Ruan, Miao
    Tian, Tian
    Rao, Jia
    Xu, Xiaoli
    Yu, Baohua
    Yang, Wentao
    Shui, Ruohong
    [J]. DIAGNOSTIC PATHOLOGY, 2018, 13
  • [22] Predictive Value of Tumor-Infiltrating Lymphocytes to Pathological Complete Response in Neoadjuvant Treated Triple-Negative Breast Cancers
    Ruan, Miao
    Tian, Tian
    Rao, Jia
    Xu, Xiaoli
    Yu, Bao-Hua
    Yang, Wentao
    Shui, Ruohong
    [J]. MODERN PATHOLOGY, 2018, 31 : 102 - 102
  • [23] Predictive Value of Tumor-Infiltrating Lymphocytes to Pathological Complete Response in Neoadjuvant Treated Triple-Negative Breast Cancers
    Ruan, Miao
    Tian, Tian
    Rao, Jia
    Xu, Xiaoli
    Yu, Bao-Hua
    Yang, Wentao
    Shui, Ruohong
    [J]. LABORATORY INVESTIGATION, 2018, 98 : 102 - 102
  • [24] Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
    Miao Ruan
    Tian Tian
    Jia Rao
    Xiaoli Xu
    Baohua Yu
    Wentao Yang
    Ruohong Shui
    [J]. Diagnostic Pathology, 13
  • [25] Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial
    Liedtke, Cornelia
    Feuerhake, Friedrich
    Garke, Madlen
    Christgen, Matthias
    Kates, Ronald E.
    Grischke, Eva-Maria
    Forstbauer, Helmut
    Braun, Michael Wilhelm
    Warm, Mathias R.
    Hackmann, Christoph
    Uleer, Christoph
    Aktas, Bahriye
    Schumacher, Claudia
    Kummel, Sherko
    Wuerstlein, Rachel
    Nitz, Ulrike
    Kreipe, Hans Heinrich
    Gluz, Oleg
    Harbeck, Nadia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
    Cornelia Kolberg-Liedtke
    Friedrich Feuerhake
    Madlen Garke
    Matthias Christgen
    Ronald Kates
    Eva Maria Grischke
    Helmut Forstbauer
    Michael Braun
    Mathias Warm
    John Hackmann
    Christoph Uleer
    Bahriye Aktas
    Claudia Schumacher
    Sherko Kuemmel
    Rachel Wuerstlein
    Monika Graeser
    Ulrike Nitz
    Hans Kreipe
    Oleg Gluz
    Nadia Harbeck
    [J]. Breast Cancer Research, 24
  • [27] Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
    Abdullaeva, S.
    Semiglazova, T. Y.
    Artemyeva, A.
    Kudaibergenova, A.
    Semiglazov, V.
    Krivorotko, P.
    Semiglazov, V.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S288 - S289
  • [28] Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
    Kolberg-Liedtke, Cornelia
    Feuerhake, Friedrich
    Garke, Madlen
    Christgen, Matthias
    Kates, Ronald
    Grischke, Eva Maria
    Forstbauer, Helmut
    Braun, Michael
    Warm, Mathias
    Hackmann, John
    Uleer, Christoph
    Aktas, Bahriye
    Schumacher, Claudia
    Kuemmel, Sherko
    Wuerstlein, Rachel
    Graeser, Monika
    Nitz, Ulrike
    Kreipe, Hans
    Gluz, Oleg
    Harbeck, Nadia
    [J]. BREAST CANCER RESEARCH, 2022, 24 (01)
  • [29] Significance of tumor-infiltrating lymphocytes in breast cancer with neoadjuvant chemotherapy
    Miyoshi, Y.
    Shien, T.
    Omori, M.
    Abe, Y.
    Watanabe, A.
    Hara, A.
    Mizoo, T.
    Nogami, T.
    Taira, N.
    Doihara, H.
    [J]. BREAST, 2015, 24 : S124 - S124
  • [30] Prognostic value of the tumor-infiltrating lymphocytes in Miller-Payne grade 4 triple-negative breast cancer following neoadjuvant chemotherapy
    Ma, Jianli
    Deng, Yuwei
    Chen, Dawei
    Li, Xiaomei
    Yu, Zhiyong
    Wang, Haibo
    Zhong, Lei
    Li, Yingjie
    Wang, Chengqin
    Zhou, Xiaoping
    Li, Xiang
    Zhang, Qingyuan
    Yu, Jinming
    [J]. CANCER RESEARCH, 2022, 82 (12)